Evaluation of the Combination of Metformin and Rapamycin in an MPP+-Treated SH-SY5Y Model of Parkinson's Disease

• Hauptverfasser: Chureerat Norradee (Verfasst von), Kawinthra Khwanraj (Verfasst von), Tatcha Balit (Verfasst von), Permphan Dharmasaroja (Verfasst von)
• Format: Buch
• Veröffentlicht: Hindawi Limited, 2023-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Metformin (MET) and rapamycin (RAPA) have been reported to protect against neurodegeneration in cellular and animal models of Parkinson's disease (PD). MET, which is a first-line drug for type 2 diabetes, and RAPA are known as mTORC1 inhibitors. MET also acts as an AMPK activator, which leads t...